Login to Your Account



Celldex Boldly Goes Alone in Pivotal Trial of Rindopepimut

By Marie Powers
Staff Writer

Friday, December 2, 2011

As expected, Celldex Therapeutics Inc. launched the randomized, double-blind, controlled Phase III trial of its cancer vaccine candidate rindopepimut (formerly CDX-110) in patients with surgically resected epidermal growth factor variant III (EGFRvIII)-positive glioblastoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription